Business strategy

The current strategy of Bionor is to further advance Vacc-4x in clinical development to develop a functional cure for HIV.

As a consequence of the new, expected ownership structure following the private placement and subsequent fully underwritten rights offering, a new Board of Directors will be elected at the extraordinary general meeting on 9 September 2016. Accordingly, the company's strategy will be evaluated by the new Board of Directors, which may lead to a reassessment of the company's current short and long-term strategies. Until such further assessments have been undertaken all planning of clinical trials is put on hold.